CN103002898A - 作为C-MET抑制剂的6-(1-甲基-1 H-吡唑-4-基)-3-(2-甲基-2H-吲唑-5-基硫代)-[l,2,4]三唑并[4,3-B]哒嗪 - Google Patents

作为C-MET抑制剂的6-(1-甲基-1 H-吡唑-4-基)-3-(2-甲基-2H-吲唑-5-基硫代)-[l,2,4]三唑并[4,3-B]哒嗪 Download PDF

Info

Publication number
CN103002898A
CN103002898A CN2011800371928A CN201180037192A CN103002898A CN 103002898 A CN103002898 A CN 103002898A CN 2011800371928 A CN2011800371928 A CN 2011800371928A CN 201180037192 A CN201180037192 A CN 201180037192A CN 103002898 A CN103002898 A CN 103002898A
Authority
CN
China
Prior art keywords
compound
cancer
compounds
methyl
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800371928A
Other languages
English (en)
Chinese (zh)
Inventor
Z.吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN103002898A publication Critical patent/CN103002898A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2011800371928A 2010-07-30 2011-07-22 作为C-MET抑制剂的6-(1-甲基-1 H-吡唑-4-基)-3-(2-甲基-2H-吲唑-5-基硫代)-[l,2,4]三唑并[4,3-B]哒嗪 Pending CN103002898A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36933510P 2010-07-30 2010-07-30
US61/369,335 2010-07-30
PCT/US2011/044926 WO2012015677A1 (en) 2010-07-30 2011-07-22 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5-

Publications (1)

Publication Number Publication Date
CN103002898A true CN103002898A (zh) 2013-03-27

Family

ID=44513148

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800371928A Pending CN103002898A (zh) 2010-07-30 2011-07-22 作为C-MET抑制剂的6-(1-甲基-1 H-吡唑-4-基)-3-(2-甲基-2H-吲唑-5-基硫代)-[l,2,4]三唑并[4,3-B]哒嗪

Country Status (15)

Country Link
US (1) US8268836B2 (cg-RX-API-DMAC10.html)
EP (1) EP2598144B1 (cg-RX-API-DMAC10.html)
JP (1) JP5738412B2 (cg-RX-API-DMAC10.html)
KR (1) KR20130052740A (cg-RX-API-DMAC10.html)
CN (1) CN103002898A (cg-RX-API-DMAC10.html)
AR (1) AR085183A1 (cg-RX-API-DMAC10.html)
AU (1) AU2011282973B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013002211A2 (cg-RX-API-DMAC10.html)
CA (1) CA2805494A1 (cg-RX-API-DMAC10.html)
EA (1) EA201270818A1 (cg-RX-API-DMAC10.html)
ES (1) ES2516940T3 (cg-RX-API-DMAC10.html)
IN (1) IN2012MN02924A (cg-RX-API-DMAC10.html)
MX (1) MX2013001247A (cg-RX-API-DMAC10.html)
TW (1) TWI431008B (cg-RX-API-DMAC10.html)
WO (1) WO2012015677A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2869316C (en) * 2012-05-09 2016-12-20 Eli Lilly And Company Anti-c-met antibodies
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10386376B2 (en) 2015-11-09 2019-08-20 Jeimei, Llc Sample container with integrated test strip
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009056692A2 (fr) * 2007-08-09 2009-05-07 Sanofi-Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
CN101553490A (zh) * 2006-10-23 2009-10-07 Sgx药品公司 用作蛋白激酶调节剂的二环三唑类化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728017B2 (en) * 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
BRPI0717320A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
EA016527B1 (ru) 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Триазолопиридазиновые модуляторы протеинкиназ
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553490A (zh) * 2006-10-23 2009-10-07 Sgx药品公司 用作蛋白激酶调节剂的二环三唑类化合物
WO2009056692A2 (fr) * 2007-08-09 2009-05-07 Sanofi-Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Also Published As

Publication number Publication date
ES2516940T3 (es) 2014-10-31
TWI431008B (zh) 2014-03-21
EA201270818A1 (ru) 2013-05-30
US8268836B2 (en) 2012-09-18
JP2013532687A (ja) 2013-08-19
BR112013002211A2 (pt) 2016-05-24
AR085183A1 (es) 2013-09-18
WO2012015677A9 (en) 2012-12-13
EP2598144A1 (en) 2013-06-05
MX2013001247A (es) 2013-03-18
WO2012015677A1 (en) 2012-02-02
IN2012MN02924A (cg-RX-API-DMAC10.html) 2015-06-12
KR20130052740A (ko) 2013-05-23
AU2011282973B2 (en) 2014-03-20
AU2011282973A1 (en) 2013-01-10
EP2598144B1 (en) 2014-08-13
JP5738412B2 (ja) 2015-06-24
US20120028984A1 (en) 2012-02-02
CA2805494A1 (en) 2012-02-02
TW201219393A (en) 2012-05-16

Similar Documents

Publication Publication Date Title
EP2598144B1 (en) 6-(1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5-ylthio)-[1,2,4] triazolo [4,3-b] pyridazine as a c-met inhibitor
EP2850082B1 (en) 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer
RU2326882C2 (ru) Пиримидиновые соединения, обладающие антипролиферативной активностью (ii)
CN109689641B (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
CN112521390A (zh) 制备parp抑制剂、结晶形式的方法及其用途
CN107922354A (zh) 作为idh2抑制剂的杂环化合物
CN109641902B (zh) 可用作人pde1抑制剂的三唑并吡嗪酮衍生物
CN107567503B (zh) 用于ttk抑制剂化疗的预后生物标记
CN113527300A (zh) 布鲁顿酪氨酸蛋白激酶抑制剂
CN112424202B (zh) 抑制cdk4/6活性化合物的晶型及其应用
WO2018177444A2 (zh) 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用
EP3661936B1 (en) [1,2,4]triazolo[4,3-a]pyrazin-6(5h)-one derivatives
EP2800566B1 (en) Therapeutic use of imidazopyridine derivatives
JP7053654B2 (ja) PI3Kβ阻害剤としてのキノキサリン及びピリドピラジン誘導体
CN110078732A (zh) 嘌呤类化合物及其用途
CN115246832A (zh) 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用
HK40040143A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
HK40037648A (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
HK40037648B (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130327